Today: 20 May 2026
Browse Category

NYSE:TMO 31 July 2025 - 4 December 2025

Thermo Fisher Scientific (TMO) Stock on December 2, 2025: Price Action, HSBC Upgrade, New Debt Deal and 2026–2030 Forecasts

Thermo Fisher Scientific (TMO) Stock on December 2, 2025: Price Action, HSBC Upgrade, New Debt Deal and 2026–2030 Forecasts

Thermo Fisher Scientific shares traded near $580 midday Tuesday, down less than 1% but close to their 52-week high of $611. HSBC raised its price target on the stock to $670. The company recently announced a €2.1 billion bond sale and a $5 billion share repurchase plan. An insider filed to sell 6,912 shares valued at about $4 million.
2 December 2025
··
Thermo Fisher Scientific (TMO) Stock on 1 December 2025: HSBC Upgrade, Insider Moves, Buyback and 2026–2030 Forecasts

Thermo Fisher Scientific (TMO) Stock on 1 December 2025: HSBC Upgrade, Insider Moves, Buyback and 2026–2030 Forecasts

Thermo Fisher Scientific shares traded at $584–585 on December 1, 2025, with a market cap near $223 billion and a P/E ratio of 34.2. HSBC upgraded the stock to “Buy” the same day, citing improved prospects. Boston Family Office increased its stake by 3% in Q2, while First National Advisers cut its position by 59%. Institutional investors hold about 89% of the float.
1 December 2025
··
Thermo Fisher Scientific (TMO) Stock News Today: Insider Selling, Institutional Buying and New Growth Moves – November 28, 2025

Thermo Fisher Scientific (TMO) Stock News Today: Insider Selling, Institutional Buying and New Growth Moves – November 28, 2025

Thermo Fisher Scientific traded near $590.83 per share late Friday, with a market cap of about $222 billion. Institutional investors, including Global Retirement Partners and Laurel Wealth Advisors, disclosed new or increased stakes. An executive vice president sold $6.43 million in shares. The stock remains near its 52-week high of just over $610.
29 November 2025
·
Thermo Fisher (TMO) Stock Surges on Biotech Boom – Analysts Eye $650 Target

Thermo Fisher (TMO) Stock Surges on Biotech Boom – Analysts Eye $650 Target

Thermo Fisher (TMO) closed at $558.07 on Oct 21, up 2.6% for the day and over 11% in October, rebounding from a 10% year-over-year dip. The company has spent $2 billion on U.S. operations and announced a $4.1 billion deal for Solventum’s filtration business. Q3 results are due Oct 22, with analysts expecting EPS of ~$5.50 and revenue near $10.91 billion. JP Morgan raised its 12-month price target to $650.
21 October 2025
·
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

U.S. stocks closed at record highs despite a partial government shutdown, with the S&P 500 up 0.34% to 6,711.20 and the Dow rising 0.09% to 46,441.10. Health-care shares jumped after Pfizer and the White House struck a drug price deal, sending Biogen up 10.9%. The ADP report showed private-sector jobs fell by 32,000 in September, but investors bet on Fed rate cuts.
1 October 2025
·····
Beyond the Eyepiece: The Next-Gen Microscopes of 2025–2026 Revolutionizing How We See the World

Beyond the Eyepiece: The Next-Gen Microscopes of 2025–2026 Revolutionizing How We See the World

Zeiss launched Lightfield 4D in March 2025, enabling instant volumetric imaging in LSM 910/990 microscopes at up to 80 stacks per second, with Microscopy Copilot AI. Nikon released the Eclipse Ti2-I in July 2025 for IVF clinics, consolidating controls and reducing workflow steps by up to 75%. Leica’s Visoria series debuted in May 2025 with tablet-based viewing and automatic metadata encoding.
31 July 2025
····
1 2 3 4

Stock Market Today

  • Celestica Inc: Over 20% Annualized Returns Anticipated Amid AI Hardware Surge
    May 19, 2026, 6:14 PM EDT. Celestica Inc (CLS) stands to gain from the growing demand for artificial intelligence (AI) hardware. This anticipated trend is expected to boost both the company's revenue (top-line) and profit margins, suggesting strong financial performance ahead. Analysts rate CLS stock as a Strong Buy, highlighting potential annualized returns exceeding 20%. Investors eyeing tech manufacturing and AI sectors may find Celestica's outlook particularly compelling amid evolving market dynamics.

Latest articles

JetBlue axes 12 routes; Fort Lauderdale responds

JetBlue axes 12 routes; Fort Lauderdale responds

20 May 2026
JetBlue will end all flights at Manchester-Boston Regional Airport on July 8 and cut nine other East Coast routes, shifting capacity to Fort Lauderdale. The move follows Spirit Airlines’ shutdown and increased competition in South Florida. JetBlue said Fort Lauderdale revenue per seat mile rose 5% in the first quarter. Manchester officials expressed disappointment, noting JetBlue made up no more than 5% of airport traffic.
Exxon, Chevron Say Oil Reserves Hit by Hormuz Choke, More Volatility Ahead

Exxon, Chevron Say Oil Reserves Hit by Hormuz Choke, More Volatility Ahead

20 May 2026
The U.S. shipped a record 9.9 million barrels from its emergency oil reserve last week, cutting stocks to 374 million barrels. Brent crude settled at $111.28 a barrel Tuesday after signs of progress in U.S.-Iran talks, but Exxon and Chevron warned the market has not fully absorbed the impact of the Strait of Hormuz closure. The IEA reported global oil inventories fell by 246 million barrels in March and April.
Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

20 May 2026
Toll Brothers shares rose 2.7% to $127.50 in after-hours trading after quarterly profit and revenue topped Wall Street forecasts. Fiscal Q2 net income fell to $260.6 million from $352.4 million a year earlier, while home sales revenue dropped to $2.51 billion. The company raised its full-year delivery and pricing guidance despite high mortgage rates and softer industry sentiment.
Go toTop